PT1303520E - Compostos terapêuticos e métodos - Google Patents

Compostos terapêuticos e métodos Download PDF

Info

Publication number
PT1303520E
PT1303520E PT01947052T PT01947052T PT1303520E PT 1303520 E PT1303520 E PT 1303520E PT 01947052 T PT01947052 T PT 01947052T PT 01947052 T PT01947052 T PT 01947052T PT 1303520 E PT1303520 E PT 1303520E
Authority
PT
Portugal
Prior art keywords
methods
therapeutic compounds
compounds
therapy
compositions
Prior art date
Application number
PT01947052T
Other languages
English (en)
Portuguese (pt)
Inventor
Barbara Martha Meurer-Grimes
Jin Yu
Gino Luigi Vairo
Original Assignee
Government Of The State Of Sar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The State Of Sar filed Critical Government Of The State Of Sar
Publication of PT1303520E publication Critical patent/PT1303520E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT01947052T 2000-07-05 2001-07-05 Compostos terapêuticos e métodos PT1303520E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPQ8665A AUPQ866500A0 (en) 2000-07-05 2000-07-05 Therapeutic compounds and methods

Publications (1)

Publication Number Publication Date
PT1303520E true PT1303520E (pt) 2008-01-07

Family

ID=3822729

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01947052T PT1303520E (pt) 2000-07-05 2001-07-05 Compostos terapêuticos e métodos

Country Status (10)

Country Link
US (1) US6710075B2 (OSRAM)
EP (1) EP1303520B1 (OSRAM)
JP (1) JP2004501983A (OSRAM)
AT (1) ATE374203T1 (OSRAM)
AU (1) AUPQ866500A0 (OSRAM)
CA (1) CA2411818C (OSRAM)
DE (1) DE60130659T2 (OSRAM)
ES (1) ES2295176T3 (OSRAM)
PT (1) PT1303520E (OSRAM)
WO (1) WO2002002566A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1569928A4 (en) * 2002-11-08 2008-12-10 Government Of The State Of Sar THERAPEUTIC COMPOUNDS AND METHOD
WO2006007634A1 (en) * 2004-07-16 2006-01-26 Cerylid Biosciences Ltd Processes and intermediates
EP2189158A1 (en) * 2008-11-20 2010-05-26 DKFZ Deutsches Krebsforschungszentrum, Stiftung des Öffentlichen Rechts Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer
WO2011140334A2 (en) * 2010-05-06 2011-11-10 Trustees Of Boston University Compounds, methods of making or identifying compounds, and uses thereof
FR3023290B1 (fr) * 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
AU2019221837B2 (en) 2018-02-19 2024-08-01 Memorial Sloan-Kettering Cancer Center Agents and methods for treating dysproliferative diseases
CN110279687A (zh) * 2019-07-15 2019-09-27 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种抗肿瘤药物
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
MY194199A (en) * 2020-08-11 2022-11-21 The Government Of The State Of Sarawak Malaysia A composition for the treatment of autoimmune diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656296A (en) 1983-06-01 1987-04-07 Sun Chemical Corporation Novel compounds and their use as insolubilizers for binders for paper coating compositions
WO1996004284A1 (en) 1994-08-04 1996-02-15 Novartis Ag Insecticidal polycyclic compounds
JPH0967360A (ja) 1995-08-28 1997-03-11 Terumo Corp 癌遺伝子機能抑制剤
WO1997008161A1 (en) 1995-08-28 1997-03-06 Terumo Kabushiki Kaisha Oncogene function depressant
JPH1112279A (ja) 1997-06-27 1999-01-19 Microbial Chem Res Found Ｒａｓ蛋白の阻害活性を有する新規なアグライアスタチン立体異性体とそれらの製造法
DE19934952A1 (de) * 1998-07-30 2000-02-03 Novartis Ag Cyclopentabenzofuran-Derivate
DE19835324A1 (de) 1998-08-05 2000-02-10 Bayer Ag Cyclopentabenzofuran-Derivate und ihre Verwendung
DE19835325A1 (de) * 1998-08-05 2000-02-10 Bayer Ag Verwendung von Cyclopentabenzofuran-Derivaten zur Bekämpfung von NF-kB abhängigen Krankheiten

Also Published As

Publication number Publication date
EP1303520A4 (en) 2005-03-30
US6710075B2 (en) 2004-03-23
CA2411818A1 (en) 2002-01-10
WO2002002566A1 (en) 2002-01-10
DE60130659D1 (de) 2007-11-08
EP1303520B1 (en) 2007-09-26
DE60130659T2 (de) 2008-07-17
ATE374203T1 (de) 2007-10-15
ES2295176T3 (es) 2008-04-16
CA2411818C (en) 2011-02-22
EP1303520A1 (en) 2003-04-23
JP2004501983A (ja) 2004-01-22
US20030181514A1 (en) 2003-09-25
AUPQ866500A0 (en) 2000-08-03

Similar Documents

Publication Publication Date Title
AU6118001A (en) Combination therapeutic compositions and methods of use
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
AU6147401A (en) Compositions and methods for the treatment of cancer
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
HUP0203968A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
PL366626A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
GB0028429D0 (en) Therapy
AU5160201A (en) Compositions comprising natural agents for treatment of cancer
EP1337255A4 (en) USE OF P38 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY COUGH
EP1435988A4 (en) IMPROVED USE OF ANTI-TUMORAL COMPOUND IN THE TREATMENT OF CANCER
GB0002386D0 (en) Therapeutic composition
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
EP1303520A4 (en) THERAPEUTIC COMPOUNDS AND METHODS
GB0018951D0 (en) Novel compounds
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
EP1349485A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF OVARIAL CARCINOMA
PL368035A1 (en) Compositions and methods for the treatment of cancer
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
GB0027705D0 (en) Novel compounds
GB0009609D0 (en) Therapeutic compositions
EP1303300A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS
IL160722A0 (en) Aryloxypropylamines as chemosensitizing agents in the treatment of cancer
AU2001285156A1 (en) Combination therapy for the treatment of migraine
GB0030857D0 (en) Therapeutic compositions
GB0018887D0 (en) Compound and their therapeutic use